Fig. 4: BRAFV600E AA treatment response to BRAFV600E inhibition. | npj Precision Oncology

Fig. 4: BRAFV600E AA treatment response to BRAFV600E inhibition.

From: BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy

Fig. 4: BRAFV600E AA treatment response to BRAFV600E inhibition.The alternative text for this image may have been generated using AI.

A Distribution of line of therapy for BRAFV600E inhibition treatment regimens. B Time-on-treatment ratio (TOTr) of the best performing prior line of 5-FU-based treatment versus BRAFV600E inhibition. Horizontal line = 1.3, arrow = still on treatment at last follow-up. C Best radiographic response (PR partial response, SD stable disease, PD progressive disease). D Longitudinal tumor marker information for Pt BRAF 15 showing CA 19-9 (U/mL, blue), CA 125 (U/mL, red), and CEA (ng/mL, gray). Shaded regions represent periods where patients were treated with the labeled chemotherapy. Dashed lines are the upper limit of the reference range for each tumor marker.

Back to article page